In reference to the earlier communications dated December 16, 2024 and January 3, 2025 wherein the Company had informed the Stock Exchange regarding resignation of Sridhar Kadangode as Chief Financial Officer of the Company and Murari Ranganathan as Commercial Director - Women’s Health, Metabolics and International Business of the Company, effective close of business hours of February 26, 2025 and February 25, 2025 respectively, to pursue opportunities outside the Company; Abbott India has informed that pursuant to Regulation 30 read with Clause 7C of Para A of Part A of Schedule Ill of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it enclosed, resignation letters of Sridhar Kadangode and Murari Ranganathan.
The above information is a part of company’s filings submitted to BSE.
